Tumor Glycomics Laboratory for Discovery of Pancreatic Cancer Markers

描述(申请人提供)：胰腺癌是美国癌症死亡的第四大原因。2006年，将有32,180人被诊断为胰腺癌，31,180人将死于胰腺癌--每小时4名美国人。胰腺癌的1年和5年预后是所有癌症中最差的(分别为4%和1%)。该病死亡率高的主要原因是缺乏早期诊断手段。因此，这种RFA应用的长期目标是将新开发的血糖学技术应用于胰腺癌血清标记物的开发。胰腺癌在某种程度上是独特的，因为它可以直接收集含有胰腺癌分泌物的胰腺导管液，而胰腺癌很可能含有潜在的糖蛋白和糖脂生物标志物。对胰腺癌和对照胰腺组织的这种液体进行血糖分析，再加上来自胰腺组织的信息，包括糖转录组分析，将使我们能够专注于特定的糖偶联物作为胰腺癌患者血清中的潜在标记物。我们的胰腺癌肿瘤糖链实验室是佐治亚大学复合碳水化合物研究中心的研究人员(包括NCRR生物医学糖链中心的成员)和凤凰城TGen研究所的临床研究人员(胰腺癌专家)之间的合作成果。目的：1.胰腺导管液和对照组(包括胰腺炎患者)的血糖分析(糖链、糖蛋白和糖鞘糖脂分析)。2.胰腺癌、正常对照和胰腺炎胰腺的糖链分析(糖链、糖蛋白、糖鞘糖脂和糖转录组分析)。3.胰腺癌潜在血清标志物的筛选及检测进展4.初步评价标记物的特异性和敏感性。用于分析的标本收集将包括TGen及其涉及世界各地26个机构的国际胰腺癌研究团队，以及NCI胰腺癌EDRN。

DESCRIPTION (provided by applicant): Pancreatic cancer is the 4th leading cause of cancer deaths in the U.S. In 2006, 32,180 will be diagnosed with pancreatic cancer and 31,180 will die from it-4 Americans every hour. Pancreatic cancer has the worst 1 and 5 year prognosis of any cancer (4% and 1%, respectively). The high mortality rate for this disease is due mainly to the lack of a means for its early diagnosis. The long-term goal of this RFA application, therefore, is to apply newly developed glycomic technologies to the development of serum markers for pancreatic carcinoma. Pancreatic cancer is somewhat unique in that it is possible to directly collect pancreatic ductal fluid that contains secretions from the cancer which is very likely to contain potential glycoprotein and glycolipid biomarkers. Glycomic analysis of this fluid from pancreatic cancers and control pancreases, coupled with information from pancreatic tissues, including glycotranscriptome analysis, will enable us to focus on specific glyconjugates as potential markers in serum from pancratic cancer patients. Our Tumor Glycomics Laboratory for Pancreatic Cancer represents a collaboration between investigators at the Complex Carbohydrate Research Center at the University of Georgia, including members of the NCRR Center for Biomedical Glycomics, and clinical researchers at the TGen Institute, Phoenix, who are pancreatic cancer specialists. Aims: 1. Glycomic analysis (glycan, glycoprotein, and glycosphingolipid analyses) of pancreatic ductal fluid and controls, including patients with pancreatitis. 2. Glycomic analysis (glycan, glycoprotein, glycosphingolipid, and glycotranscriptome analyses) of pancreatic carcinoma, non-diseased controls, and pancreases exhibiting pancreatitis. 3. Identification of potential serum markers of pancreatic carcinoma and assay development. 4. Initial evaluation specificity and sensitivity of markers. Collection of specimens for analysis will involve TGen and its international Pancreatic Cancer Research Team that involves 26 institutions world-wide, as well as the NCI EDRN for Pancreatic Cancer.